Torrent Pharmaceuticals Limited (TORNTPHARM) - Total Assets

Latest as of March 2026: Rs443.12 Billion INR ≈ $4.79 Billion USD

Based on the latest financial reports, Torrent Pharmaceuticals Limited (TORNTPHARM) holds total assets worth Rs443.12 Billion INR (≈ $4.79 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check TORNTPHARM cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Torrent Pharmaceuticals Limited - Total Assets Trend (2005–2026)

This chart illustrates how Torrent Pharmaceuticals Limited's total assets have evolved over time, based on quarterly financial data. Explore Torrent Pharmaceuticals Limited (TORNTPHARM) long-term investment share to see how much of total assets are deployed in long-term investments.

Torrent Pharmaceuticals Limited - Asset Composition Analysis

Current Asset Composition (March 2026)

Torrent Pharmaceuticals Limited's total assets of Rs443.12 Billion consist of 21.2% current assets and 78.8% non-current assets.

Asset Category Amount (INR) % of Total Assets
Cash & Equivalents Rs0.00 2.6%
Accounts Receivable Rs30.36 Billion 6.9%
Inventory Rs31.38 Billion 7.1%
Property, Plant & Equipment Rs0.00 0.0%
Intangible Assets Rs244.64 Billion 55.2%
Goodwill Rs39.90 Billion 9.0%

Asset Composition Trend (2005–2026)

This chart illustrates how Torrent Pharmaceuticals Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Torrent Pharmaceuticals Limited stock valuation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Torrent Pharmaceuticals Limited's current assets represent 21.2% of total assets in 2026, a decrease from 37.3% in 2005.
  • Cash Position: Cash and equivalents constituted 2.6% of total assets in 2026, up from 1.5% in 2005.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 64.0% of total assets, an increase from 13.0% in 2005.
  • Asset Diversification: The largest asset category is intangible assets at 55.2% of total assets.

Torrent Pharmaceuticals Limited Competitors by Total Assets

Key competitors of Torrent Pharmaceuticals Limited based on total assets are shown below.

Company Country Total Assets
Yunnan Baiyao Group Co Ltd
SHE:000538
China CN¥53.34 Billion
Sandoz Group AG
SW:SDZ
Switzerland CHF22.03 Billion
Haleon plc
NYSE:HLN
USA $32.57 Billion
Viatris Inc
NASDAQ:VTRS
USA $36.83 Billion
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
China CN¥19.57 Billion
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601
China CN¥13.99 Billion
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
China CN¥5.17 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion

Torrent Pharmaceuticals Limited - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.13 1.19 1.13
Quick Ratio 0.75 0.65 0.58
Cash Ratio 0.00 0.12 0.00
Working Capital Rs10.49 Billion Rs9.06 Billion Rs6.30 Billion

Torrent Pharmaceuticals Limited - Advanced Valuation Insights

This section examines the relationship between Torrent Pharmaceuticals Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 17.79
Latest Market Cap to Assets Ratio 0.04
Asset Growth Rate (YoY) 195.6%
Total Assets Rs443.12 Billion
Market Capitalization $16.49 Billion USD

Valuation Analysis

Below Book Valuation: The market values Torrent Pharmaceuticals Limited's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Torrent Pharmaceuticals Limited's assets grew by 195.6% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Torrent Pharmaceuticals Limited (2005–2026)

The table below shows the annual total assets of Torrent Pharmaceuticals Limited from 2005 to 2026.

Year Total Assets Change
2026-03-31 Rs443.12 Billion
≈ $4.79 Billion
+195.61%
2025-03-31 Rs149.90 Billion
≈ $1.62 Billion
-0.47%
2024-03-31 Rs150.61 Billion
≈ $1.63 Billion
+0.32%
2023-03-31 Rs150.12 Billion
≈ $1.62 Billion
+14.60%
2022-03-31 Rs131.00 Billion
≈ $1.42 Billion
-6.93%
2021-03-31 Rs140.75 Billion
≈ $1.52 Billion
+0.26%
2020-03-31 Rs140.38 Billion
≈ $1.52 Billion
-0.59%
2019-03-31 Rs141.21 Billion
≈ $1.53 Billion
-0.86%
2018-03-31 Rs142.43 Billion
≈ $1.54 Billion
+40.67%
2017-03-31 Rs101.25 Billion
≈ $1.09 Billion
+12.33%
2016-03-31 Rs90.14 Billion
≈ $974.79 Million
+13.94%
2015-03-31 Rs79.11 Billion
≈ $855.55 Million
+56.04%
2014-03-31 Rs50.70 Billion
≈ $548.28 Million
+34.02%
2013-03-31 Rs37.83 Billion
≈ $409.10 Million
+23.08%
2012-03-31 Rs30.74 Billion
≈ $332.39 Million
+20.61%
2011-03-31 Rs25.48 Billion
≈ $275.60 Million
+29.68%
2010-03-31 Rs19.65 Billion
≈ $212.52 Million
+17.85%
2009-03-31 Rs16.67 Billion
≈ $180.33 Million
+31.73%
2008-03-31 Rs12.66 Billion
≈ $136.90 Million
+21.14%
2007-03-31 Rs10.45 Billion
≈ $113.01 Million
+10.94%
2006-03-31 Rs9.42 Billion
≈ $101.86 Million
+32.54%
2005-03-31 Rs7.11 Billion
≈ $76.85 Million
--

About Torrent Pharmaceuticals Limited

NSE:TORNTPHARM India Drug Manufacturers - Specialty & Generic
Market Cap
$16.49 Billion
Rs1.52 Trillion INR
Market Cap Rank
#1532 Global
#49 in India
Share Price
Rs4504.00
Change (1 day)
-1.47%
52-Week Range
Rs3164.00 - Rs4572.60
All Time High
Rs4572.60
About

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, Malta, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, CNS, urology, gynecology, oncology, gastro-int… Read more